EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proteo‐Metabolomic Profiling of PMM2 ‐ CDG Reveals Dysregulation of Retinoic Acid Synthesis, Myo ‐Inositol, and the Hexosamine Pathway

Diana Gallego iD, Giuseppina Andreotti iD, Maria Monticelli iD, Debora Paris iD, Arturo Martín-Martínez, Alejandra Gámez iD, Mercedes Serrano iD, José Córdoba-Caballero, Pedro Seoane iD, Juan A G Ranea, Belén Pérez iD

Journal of Inherited Metabolic Disease · 2026-09 · 49 (5)

DOI: 10.1002/jimd.70233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 13.08.2026. Verfasst von Diana Gallego und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Diagnóstico de Enfermedades Moleculares. Centro de Biología Molecular, Universidad Autónoma de Madrid. CIBERER. IdiPAZ, Madrid, Spain. Hauptthemen laut MEDLINE: Inositol, Hexosamines, Phosphotransferases (Phosphomutases), Tretinoin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Regione Campania, Fundación Ramón Areces.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phosphomannomutase deficiency (PMM2‐CDG), the most common congenital disorder of glycosylation (CDG), is characterized by multisystem involvement and a lack of disease‐modifying therapies. While previous transcriptomic studies have uncovered disrupted cellular pathways, the functional consequences of these alterations remain poorly understood. To further investigate PMM2‐CDG pathophysiology, we integrated proteomic and metabolomic profiling of patient‐derived fibroblasts with previously published transcriptomic data. Proteomic analysis was performed using Tandem Mass Tag‐based mass spectrometry, while metabolomics was conducted via Nuclear Magnetic Resonance spectroscopy. Multi‐omics integration was performed using principal component analysis–based dimensionality reduction, incorporating clinical metadata as supplementary variables. Proteomic analysis identified 43 significantly altered proteins, with enrichment in the retinoic acid synthesis pathway, wound healing, and cytoskeletal organization. Metabolomic profiling revealed altered amino acid levels and elevated concentrations of UDP‐GlcNAc, consistent with perturbation of the hexosamine biosynthesis pathway, and increased levels of my o ‐inositol. Notably, myo ‐inositol levels showed a strong association with disease severity in the integrated analysis. RT‐qPCR confirmed the upregulation of GFPT2 . This integrative multi‐omics study identifies consistent alterations in the retinoic acid synthesis pathway and hexosamine biosynthesis in PMM2‐CDG patient‐derived fibroblasts and reveals an association between intracellular myo ‐inositol levels and disease severity. These findings provide new insights into PMM2‐CDG–associated molecular alterations and illustrate the value of multi‐omics integration for hypothesis generation in rare diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InositolHexosaminesPhosphotransferases (Phosphomutases)TretinoinCongenital Disorders of GlycosylationHumansMetabolomicsFibroblastsProteomicsMultiomics

Stichwörter der Autor:innen

PMM2‐CDGhexosamine pathwaymetabolomicsmyo‐inositolproteomicsretinoic acidretinol

Substanzen

InositolHexosaminesPhosphotransferases (Phosphomutases)Tretinoinphosphomannomutase 2, human

Autor:innen und Institutionen

  • Centro de Diagnóstico de Enfermedades Moleculares. Centro de Biología Molecular, Universidad Autónoma de Madrid. CIBERER. IdiPAZ, Madrid, Spain.
  • Institute of Biomolecular Chemistry (ICB), National Research Council of Italy, Naples, Italy.
  • UniCamillus - Saint Camillus International University of Health Sciences, Rome, Italy.
  • Pediatric Neurology Department, Hospital Sant Joan de Déu, Barcelona, Spain and Institut de Recerca Sant Joan de Déu, CIBERER, Barcelona, Spain.
  • Department of Molecular Biology and Biochemistry, University of Malaga, 29010, Malaga, Spain. CIBERER. Institute of Biomedical Research in Malaga and Platform of Nanomedicine, IBIMA Plataforma BIONAND, 29071, Malaga, Sp…

ORCID-Profile: Diana Gallego, Giuseppina Andreotti, Maria Monticelli, Debora Paris, Alejandra Gámez, Mercedes Serrano, Pedro Seoane, Belén Pérez

Förderung

  • Instituto de Salud Carlos III
  • Regione Campania
  • Fundación Ramón Areces

Zitieren

APA

Gallego, D., Andreotti, G., Monticelli, M., Paris, D., Martín-Martínez, A., Gámez, A., Serrano, M., Córdoba-Caballero, J., Seoane, P., Ranea, J. A. G., & Pérez, B. (2026). Proteo‐Metabolomic Profiling of PMM2 ‐ CDG Reveals Dysregulation of Retinoic Acid Synthesis, Myo ‐Inositol, and the Hexosamine Pathway. Journal of Inherited Metabolic Disease, 49(5). https://doi.org/10.1002/jimd.70233

Vancouver

Gallego D, Andreotti G, Monticelli M, Paris D, Martín-Martínez A, Gámez A, et al. Proteo‐Metabolomic Profiling of PMM2 ‐ CDG Reveals Dysregulation of Retinoic Acid Synthesis, Myo ‐Inositol, and the Hexosamine Pathway. Journal of Inherited Metabolic Disease. 2026;49(5). doi:10.1002/jimd.70233

BibTeX
@article{Gallego2026,
  author = {Gallego, Diana and Andreotti, Giuseppina and Monticelli, Maria and Paris, Debora and Martín-Martínez, Arturo and Gámez, Alejandra and Serrano, Mercedes and Córdoba-Caballero, José and Seoane, Pedro and Ranea, Juan A G and Pérez, Belén},
  title = {Proteo‐Metabolomic Profiling of PMM2 ‐ CDG Reveals Dysregulation of Retinoic Acid Synthesis, Myo ‐Inositol, and the Hexosamine Pathway},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2026},
  volume = {49},
  number = {5},
  doi = {10.1002/jimd.70233}
}
Kostenlos starten →